Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President and CEO

Chief Financial Officer

Chief Medical Officer

Chief Oper. & Tech. Officer

Chief Scientific Officer

Chief Legal Officer

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address gene...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-15	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-04-15	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-19	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-14	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-03-14	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-05	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-14	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-16	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-16	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Oper. & Tech. Officer
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Legal Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Oper. & Tech. Officer
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-12-19	Premium	acquired	Premium	Premium	Premium	President and CEO

RGNX - REGENXBIO Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RGNX